XORTX Therapeutics (XRTX) EBITDA Margin (2022 - 2023)
XORTX Therapeutics (XRTX) posted EBITDA Margin of 183.21% for Q4 2023, down 30.78% on a QoQ basis from 140.09% in Q3 2023, and down 11204.0% year-over-year from N/an in Q4 2022.
XORTX Therapeutics (XRTX) EBITDA Margin (2022 - 2023) Analysis & Trends
XORTX Therapeutics' EBITDA Margin history runs 2 years deep, the most recent figure standing at 183.21% for Q4 2023.
- Quarterly EBITDA Margin fell 11204.0% year-over-year to 183.21% in Q4 2023, while the trailing twelve-month figure through Dec 2023 was 54.46% (up 4668.0% YoY) and the FY2023 annual result came in at 95.2%, up 41843.0% from the prior year.
- EBITDA Margin was 183.21% for Q4 2023 at XORTX Therapeutics, down from 140.09% in the prior quarter.
- Across five years, EBITDA Margin topped out at 71.17% in Q4 2022 and bottomed at 183.21% in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 16.51% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | XORTX Therapeutics | 2.91 Bn | 2.91 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -183.21% |
| Sep 30, 2023 | -140.09% |
| Jun 30, 2023 | -100.00% |
| Mar 31, 2023 | -99.90% |
| Dec 31, 2022 | -71.17% |
| Sep 30, 2022 | -96.13% |
| Jun 30, 2022 | -98.79% |
| Mar 31, 2022 | -134.56% |